Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Total Valuation
Evaxion Biotech has a market cap or net worth of $2.09M. The enterprise value is ―.
Market Cap$2.09M
Enterprise Value―
Share Statistics
Evaxion Biotech has 6,316,572 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,316,572
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Evaxion Biotech’s return on equity (ROE) is 4.68 and return on invested capital (ROIC) is -340.71%.
Return on Equity (ROE)4.68
Return on Assets (ROA)-1.72
Return on Invested Capital (ROIC)-340.71%
Return on Capital Employed (ROCE)-3.82
Revenue Per Employee1.59K
Profits Per Employee-480.98K
Employee Count46
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Evaxion Biotech is -1.06. Evaxion Biotech’s PEG ratio is >-0.01.
PE Ratio-1.06
PS Ratio0.00
PB Ratio32.85
Price to Fair Value-4.95
Price to FCF-0.28
Price to Operating Cash Flow-1.21
PEG Ratio>-0.01
Income Statement
In the last 12 months, Evaxion Biotech had revenue of 73.00K and earned -22.13M in profits. Earnings per share was -1.62.
Revenue73.00K
Gross Profit72.89K
Operating Income-22.20M
Pretax Income-22.91M
Net Income-22.13M
EBITDA-21.40M
Earnings Per Share (EPS)-1.62
Cash Flow
In the last 12 months, operating cash flow was -2.01M and capital expenditures 1.00K, giving a free cash flow of -2.01M billion.
Operating Cash Flow-2.01M
Free Cash Flow-2.01M
Free Cash Flow per Share-0.32
Dividends & Yields
Evaxion Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change-92.10%
50-Day Moving Average1.64
200-Day Moving Average7.78
Relative Strength Index (RSI)45.54
Average Volume (3m)70.20K
Important Dates
Evaxion Biotech upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Evaxion Biotech as a current ratio of 1.18, with Debt / Equity ratio of 0.00%
Current Ratio1.18
Quick Ratio1.18
Debt to Market Cap0.37
Net Debt to EBITDA-0.25
Interest Coverage Ratio-24.75
Taxes
In the past 12 months, Evaxion Biotech has paid -791.22K in taxes.
Income Tax-791.22K
Effective Tax Rate0.03
Enterprise Valuation
Evaxion Biotech EV to EBITDA ratio is -22.14, with an EV/FCF ratio of -26.65.
EV to Sales6.49K
EV to EBITDA-22.14
EV to Free Cash Flow-26.65
EV to Operating Cash Flow-26.78
Balance Sheet
Evaxion Biotech has $4.58M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$4.58M billion.
Cash & Marketable Securities$4.58M
Total Debt$0.00
Net Cash-$4.58M
Net Cash Per Share-$0.72
Tangible Book Value Per Share-$0.35
Margins
Gross margin is 100.00%, with operating margin of -30406.85%, and net profit margin of -30308.22%.
Gross Margin100.00%
Operating Margin-30406.85%
Pretax Margin-31390.41%
Net Profit Margin-30308.22%
EBITDA Margin-29319.18%
EBIT Margin-30161.64%
Analyst Forecast
The average price target for Evaxion Biotech is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside571.14% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast4455.07%
EPS Growth Forecast77.31%